ResMed (NYSE:RMD) supports global respiratory care as s&p 500 chart discussions frame large healthcare organizations.

ResMed is betting big on artificial intelligence (AI) to boost CPAP adherence. At the recent J.P. Morgan Healthcare Conference, CEO Mick Farrell said the company’s first AI-enabled medical device, Sma ...

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact ...

Resmed has announced that Kylie Canaday has been appointed chief strategy officer, officially stepping into the role on Jan. 16.

Since July 2025, ResMed has been in a holding pattern, floating around $254.41. The stock also fell short of the S&P 500’s 11 ...

Canaday was named chief of staff for the executive team at Resmed in January 2022. Later that year, she moved into the ...

In its recent past quarterly update, ResMed reported US$1.34 billion in revenue, growing around 9% year on year, with earnings per share ahead of analyst expectations while revenue aligned with ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...

When Philips first began its massive recall of more than 5 million CPAP and BiPAP machines and other ventilators in mid-2021, its competitor ResMed swooped in to fill the void left behind—seemingly ...

ResMed is on a mission to cement the lead it’s built while competitor Philips has been out of the CPAP machine-making game. That process of building out its market share for the long-term has recently ...

A replay of the earnings webcast will be accessible on Resmed’s investor relations website and available approximately two hours after the webcast. In addition, a phone replay will be available ...

ResMed (NYSE: RMD), a medical equipment company, has seen an 18% fall in a month, underperforming the broader S&P500 index, up 1%. The recent fall can be attributed to its downbeat Q4 fiscal 2023 ...